CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Trial Details

NCT ID

NCT06355739

Phase

NA

Sponsor

Zhu Xiaofan

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

• CAR T cell injection

Locations (sample)

• Tianjin, Tianjin Municipality, China|39.14222,117.17667
• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• 1, age 3-18 years old (including boundary value), male and female;
• 2\. The patient was clinically diagnosed as relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoblastic
• Patients with tumors who meet one of the following conditions:
• Complete marrow response (MRD\>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.